Solskin I highlighted Charles River Laboratories's (NYSE:CRL) near-term challenges due to the weak biopharma market, initiating with a 'Hold' rating in my previous coverage published in February 2024. The company released its Q2 result on August 7th, lowering its full-year guidance due to weak demands from small and mid-sized biotechnology customers. I think the current stock price has already factored in the softness of biopharma market, making it an opportune time to invest in this highquality company. Th ...